CLDN9: Another Key Regulator for Tumors or Hearing Loss from the CLDN Family!Presently, ample research suggested that CLDN family members are partly responsible for the development and progression of various malignancies, making them promising target candidates for cancer therapy. For example, CL...
Detailed information

CLDN6: A "New Favorite" in Targeted Cancer Therapy after CLDN 18.2!In September 2024, Daiichi Sankyo announced the Phase I clinical trial results of DS-9606, an antibody-drug conjugate (ADC) targeting Claudin-6 (CLDN6) developed based on an ADC platform. In the dose-escalation phase of ...
Detailed information

Recombinant Monkeypox Virus Proteins - Accelerate Monkeypox ResearchThe World Health Organization (WHO) declared the 2022 monkeypox outbreak a Public Health Emergency of International Concern (PHEIC) on 23 July 2022 local time [1]. On July 27, the WHO reported more than 18,000 cases of m...
Detailed information

SSTR2: A Prominent Target in SSTR Family, Offers a More Precise Therapy in Neuroendocrine Tumors (NET)Recently, Sanofi invested $20 million to gain priority negotiation rights for Zucara Therapeutics' novel SSTR2-targeting drug candidate ZT-01 for type 1 diabetes. ZT-01, an SSTR2 receptor antagonist, could prevent hypogl...
Detailed information

SEMA4D/CD100: As an Important Immunoregulator to Improve ImmunotherapyIn April 2022, the American Association for Cancer Research (AACR) annual meeting announced phase 1b/2 clinical data (NCT04815720) for Pepinemab, the first SEMA4D-targeted antibody for the treatment of recurrent or metas...
Detailed information

GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!On April 19, 2022, Innovative Cellular Therapeutics (ICT) company from Shanghai, China receives FDA Fast Track Designation for GCC19CART. GCC19CART is a CAR-T cell therapy based on ICT's unique CoupledCAR® technology...
Detailed information

ROR1, an Emerging Target for Tumor ImmunotherapyROR1 has emerged as a key target, with multiple pharmaceutical companies advancing ROR1-targeted drugs into clinical trials. Recently, Merck & Co. acquired Zilovertamab Vedotin (MK-2140) for $2.75 billion, and its clinic...
Detailed information

TFPI: a Natural Anticoagulant Protein, Future Therapies for HemophiliaPfizer announced that its TFPI antibody, Marstacimab (brand name Hympavzi), has been approved by the FDA. This marks a significant advance in hemophilia treatment. Hympavzi is the first FDA-approved TFPI antibody and pro...
Detailed information

TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!AstraZeneca and Neurimmune Therapeutics have signed an agreement on Mar. 1, 2022, contributing about $700 million cooperation on NI006 clinical research. NI006 is a transthyretin (TTR) targeting modulator for rare diseas...
Detailed information

DT3C, a Powerful Tool for ADC Drug Internalization In VitroHighlight 1. Can simulate ADC drug function in vitro. 2. Simple preparation of mAb–DT3C complexes. 3. Can combine with mAbs from multiple sources. 4. Antibody internaliza...
Detailed information